RT Journal Article
SR Electronic
T1 Decoding biological age from face photographs using deep learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.12.23295132
DO 10.1101/2023.09.12.23295132
A1 Zalay, Osbert
A1 Bontempi, Dennis
A1 Bitterman, Danielle S
A1 Birkbak, Nicolai
A1 Shyr, Derek
A1 Haugg, Fridolin
A1 Qian, Jack M
A1 Roberts, Hannah
A1 Perni, Subha
A1 Prudente, Vasco
A1 Pai, Suraj
A1 Dekker, Andre
A1 Haibe-Kains, Benjamin
A1 Guthier, Christian
A1 Balboni, Tracy
A1 Warren, Laura
A1 Krishan, Monica
A1 Kann, Benjamin H
A1 Swanton, Charles
A1 Ruysscher, Dirk De
A1 Mak, Raymond H
A1 Aerts, Hugo JWL
YR 2023
UL http://medrxiv.org/content/early/2023/09/12/2023.09.12.23295132.abstract
AB Because humans age at different rates, a person’s physical appearance may yield insights into their biological age and physiological health more reliably than their chronological age. In medicine, however, appearance is incorporated into medical judgments in a subjective and non-standardized fashion. In this study, we developed and validated FaceAge, a deep learning system to estimate biological age from easily obtainable and low-cost face photographs. FaceAge was trained on data from 58,851 healthy individuals, and clinical utility was evaluated on data from 6,196 patients with cancer diagnoses from two institutions in the United States and The Netherlands. To assess the prognostic relevance of FaceAge estimation, we performed Kaplan Meier survival analysis. To test a relevant clinical application of FaceAge, we assessed the performance of FaceAge in end-of-life patients with metastatic cancer who received palliative treatment by incorporating FaceAge into clinical prediction models. We found that, on average, cancer patients look older than their chronological age, and looking older is correlated with worse overall survival. FaceAge demonstrated significant independent prognostic performance in a range of cancer types and stages. We found that FaceAge can improve physicians’ survival predictions in incurable patients receiving palliative treatments, highlighting the clinical utility of the algorithm to support end-of-life decision-making. FaceAge was also significantly associated with molecular mechanisms of senescence through gene analysis, while age was not. These findings may extend to diseases beyond cancer, motivating using deep learning algorithms to translate a patient’s visual appearance into objective, quantitative, and clinically useful measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge financial support from NIH (HA: NIH-USA U24CA194354, NIH-USA U01CA190234, NIH-USA U01CA209414, and NIH-USA R35CA22052; BHK: NIH-USA K08DE030216-01), and the European Union – European Research Council (HA: 866504).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study and its protocols were approved by the independent hospital ethics review boards at Mass General Brigham (MGB) and Dana-Farber Harvard Cancer Center, Boston MA, and Maastricht University, Maastricht, The Netherlands. All clinical data were handled in compliance with respective institutional research policies.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesA part of the data produced in the present study (e.g., data that are not linked to patients) is available upon reasonable request to the authors.